Your email has been successfully added to our mailing list.

×
-0.00324205007932686 -0.00841553424846519 -0.0239359867558806 -0.029109470925019 -0.0308339656480652 -0.0187625025867422 -0.00798441056770374 -0.0325584603711113
Stock impact report

SciSparc's subsidiary MitoCareX approved for acquisition by N2OFF shareholders; shares up 29% [Seeking Alpha]

SciSparc Ltd. (SPRC) 
Company Research Source: Seeking Alpha
Upon closing, MitoCareX will become a wholly owned subsidiary of N2OFF, focused on mitochondrial protein-targeted therapies for hard-to-treat cancers. Deal terms include $700K cash to SciSparc and 40% of N2OFF's fully diluted stock to MitoCareX shareholders, with future milestone-based stock issuances and 30% share in financing proceeds (capped at $1.6M). N2OFF has committed to a $1M initial investment and ongoing support for two years post-closing. Final closing is targeted for early October 2025. SPRC shares up 28.7% post-market on Monday. Source: Press release More Trending News Show less Read more
Impact Snapshot
Event Time:
SPRC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for SPRC alerts
Opt-in for
SPRC alerts

from News Quantified
Opt-in for
SPRC alerts

from News Quantified